Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
Antithrombotic, haemorrhagic and anticoagulant effects of unfractionated heparin (UH) and the low molecular weight heparin fragment KABI 2165 were studied in rats. In stasis-induced venous thrombosis of the jugular vein intravenous injection of both, UH and KABI 2165, either reduced significantly the size of thrombi or completely prevented thrombus formation in a dose-dependent manner. The dose of KABI 2165 required for prevention of thrombus formation showed a marked anticoagulant activity measured by APTT which was in the same range as that of the equieffective dose of UH. After administration of antithrombotically effective doses only UH caused a significant prolongation of bleeding time after standardized incision of the tail. KABI 2165 produced haemorrhagic effects at about 4-fold higher doses only than those required for the antithrombotic action.
Kaiser
B
B
Institute of Pharmacology and Toxicology, Medical Academy Erfurt, GDR.
Hauptmann
J
J
Markwardt
F
F
D000818:Animals; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006470:Hemorrhage / Q000097:blood* / Q000139:chemically induced; D006487:Hemostasis / Q000187:drug effects; D006493:Heparin / Q000494:pharmacology*; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology*; D008297:Male; D010314:Partial Thromboplastin Time; D051381:Rats; D011919:Rats, Inbred Strains; D013918:Thrombin Time; D013924:Thrombophlebitis / Q000097:blood / Q000209:etiology
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin